Skip to content

Bio-Rad Laboratories

US · BIO #1479 by market cap Listed 1970
358.90 -8.60 -2.34%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 367.50 0.00%
After-hours 358.90 0.00%
390.34270.32358.902026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on BIO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +6.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 4.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation C

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 9.5x Better than 83%
Forward P/E 43.1x Better than 9%
Price / Sales 3.8x Better than 31%
P/E vs own 5-yr range 81st pctl Better than 25%
Growth A-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) -2.7% Better than 16%
Net income CAGR (3Y) 126.6% Better than 97%
Free cash flow CAGR (3Y) 67.2% Better than 88%
Profitability B+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 51.9% Better than 65%
Operating margin 8.5% Better than 46%
Net margin 29.4% Better than 89%
Return on equity 10.8% Better than 55%
Return on invested capital 8.6% Better than 63%
Momentum A-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -5.6% Better than 61%
6-month return 24.7% Better than 86%
12-month return (ex latest month) 16.8% Better than 55%
Distance below 52-week high 9.4% Better than 85%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 5.6x Better than 88%
Debt to assets 13.1% Better than 65%
Interest coverage 21.3x Better than 83%
Free cash flow / net income 49.3% Better than 13%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -2.04%
1M +1.24%
3M -4.66%
6M +24.68%
YTD +18.45%
1Y +18.21%
3Y +17.86%
5Y -53.79%

Key statistics

Price & volume

Prev close
367.50
Open
364.34
Day range
353.31 - 369.44
Avg price
360.56
Volume
182.30K
Turnover
65.73M
Amplitude
4.39%
52-week range
236.73 - 396.23

Valuation

P/E
12.89
P/E (TTM)
9.54
P/B
1.27
EPS
27.85
Net profit
748.97M
Net assets
7.60B

Share structure

Market cap
9.65B
Float cap
7.72B
Shares out
26.89M
Float shares
21.50M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 77% of range
236.73 396.23

9.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-11.41M net over the window

Short interest

Shares short
1.16M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Bio-Rad Laboratories (BIO)?

Bio-Rad Laboratories last traded at 358.90. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Bio-Rad Laboratories's market cap?

About 9.65B.

What is the P/E ratio of Bio-Rad Laboratories?

The trailing twelve-month P/E is 9.54. The Valuation tab shows it against the stock's own five-year range.

Does Bio-Rad Laboratories pay a dividend?

Bio-Rad Laboratories does not currently pay a regular dividend.

Is Bio-Rad Laboratories a buy according to analysts?

The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 440.00, which implies 22.6% upside from the current price. This is not investment advice.

What is Bio-Rad Laboratories's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Bio-Rad Laboratories a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Bio-Rad Laboratories discussion 0 comments

Add a comment